AOD-9604 + CJC-1295 + Ipamorelin (12 mg Blend) Dosage Protocol

AOD-9604 + CJC-1295 + Ipamorelin Dosage Chart

This synergistic blend combines three peptides targeting body composition: AOD-9604 (hGH fragment 177–191) promotes lipolysis without raising IGF-1^[1]; CJC-1295 (GHRH analog) produces sustained GH and IGF-1 elevations^[2]; and Ipamorelin (ghrelin mimetic) selectively stimulates GH secretion without increasing cortisol or ACTH^[3]. Together, these peptides may support lean mass gains and fat reduction^[4].

Related research: For distinct compound, component, or formulation evidence and safety context, read AOD-9604 Peptide: Benefits, Uses, Side Effects, Dosage, and Research, Ipamorelin Peptide: Benefits, Uses, Side Effects, Dosage, and Research, and CJC-1295 DAC Peptide: Benefits, Uses, Side Effects, Dosage, and Research. These links are comparisons only; the compounds and formulations should not be treated as interchangeable.

Dosing & Reconstitution Guide

Educational guide for reconstitution and daily dosing

Standard / Gradual Approach (3 mL reconstitution)

Concentration after reconstitution: 2.0 mg/mL AOD-9604 | 1.0 mg/mL CJC-1295 | 1.0 mg/mL Ipamorelin

Frequency: Inject once daily subcutaneously, preferably in the morning or before bed on an empty stomach. For ≤10‑unit (≤0.10 mL) administrations during titration, consider 30‑ or 50‑unit insulin syringes for improved readability.

Reconstitution Steps

1. Draw 3.0 mL bacteriostatic water with a sterile syringe.
2. Inject slowly down the vial wall; avoid foaming.
3. Gently swirl/roll until dissolved (do not shake).
4. Label and refrigerate at 2–8 °C (35.6–46.4 °F), protected from light.

Syringe Math Reference

Using a U-100 insulin syringe (100 units = 1 mL):

• 1 unit (0.01 mL) = 20 mcg AOD + 10 mcg CJC + 10 mcg Ip
• 10 units (0.10 mL) = 200 mcg AOD + 100 mcg CJC + 100 mcg Ip
• 15 units (0.15 mL) = 300 mcg AOD + 150 mcg CJC + 150 mcg Ip
• 20 units (0.20 mL) = 400 mcg AOD + 200 mcg CJC + 200 mcg Ip

Protocol Overview

Concise summary of the once‑daily regimen.

• Goal: Support body composition improvements through combined lipolytic and GH-stimulating mechanisms^[4][5].
• Schedule: Daily subcutaneous injections for 8–12 weeks (extend to 16 weeks if desired).
• Dose Range: 200–400 mcg AOD / 100–200 mcg CJC / 100–200 mcg Ip daily with gradual titration.
• Reconstitution: 3.0 mL per 12 mg vial (4 mg/mL total concentration).
• Storage: Lyophilized frozen; reconstituted refrigerated; avoid repeated freeze–thaw.

Dosing Protocol

Suggested daily titration approach.

• Start: 0.10 mL daily (200 mcg AOD / 100 mcg CJC / 100 mcg Ip); increase by ~0.05 mL weekly as tolerated.
• Target: 0.20 mL daily (400 mcg AOD / 200 mcg CJC / 200 mcg Ip) by Week 3.
• Frequency: Once per day (subcutaneous).
• Cycle Length: 8–12 weeks; optional extension to 16 weeks.
• Timing: Morning or before bed on an empty stomach; rotate injection sites.

Storage Instructions

Proper storage preserves peptide quality.

• Lyophilized: Store at −20 °C (−4 °F) in dry, dark conditions; minimize moisture exposure.
• Reconstituted: Refrigerate at 2–8 °C (35.6–46.4 °F); use within 28 days per CDC/USP guidelines^[6].
• Allow vials to reach room temperature before opening to reduce condensation uptake.

Important Notes

Practical considerations for consistency and safety.

• Use new sterile insulin syringes for each injection; dispose in a sharps container.
• Rotate injection sites (abdomen, thighs, upper arms) to reduce local irritation.
• Inject slowly; wait a few seconds before withdrawing the needle.
• Document daily dose and site rotation to maintain consistency.
• Best administered on an empty stomach (fasting) for optimal GH release.

How This Works

This blend combines three complementary peptides with distinct mechanisms:

• AOD-9604 is a modified C-terminal fragment of human growth hormone (amino acids 177–191) that retains the lipolytic and anti-lipogenic properties of GH without stimulating IGF-1 or affecting glucose metabolism^[1][7].
• CJC-1295 is a long-acting GHRH analog that produces sustained elevations in growth hormone and IGF-1 levels^[2], supporting anabolic processes and fat metabolism.
• Ipamorelin is a selective ghrelin mimetic that stimulates pulsatile GH secretion without significantly increasing ACTH or cortisol^[3], offering a cleaner GH release profile.

Together, these peptides work synergistically to enhance endogenous GH pulsatility and promote favorable changes in body composition similar to exogenous GH therapy^[4][5].

Potential Benefits & Side Effects

Observations from preclinical and clinical literature.

Potential Benefits

• Supports reduction in fat mass and enhancement of lipolysis^[1][5].
• May promote lean mass gains through sustained GH and IGF-1 elevation^[2][4].
• Selective GH release without significant cortisol or prolactin increases^[3].
• AOD-9604 shows a placebo-like safety profile in human studies^[7][8].

Possible Side Effects

• Mild injection-site reactions (redness, itching) with subcutaneous administration.
• Transient flushing or warmth following injection.
• Occasional headache or lightheadedness during initial use.
• Water retention (typically mild) with sustained GH elevation.

Lifestyle Factors

Complementary strategies for best outcomes.

• Pair with a balanced, protein-forward diet tailored to energy needs.
• Combine resistance training and aerobic activity to reinforce metabolic adaptations.
• Prioritize quality sleep (7–9 hours) to maximize endogenous GH release.
• Manage stress to optimize hormonal balance and recovery.
• Stay hydrated and maintain consistent meal timing.

Injection Technique

General subcutaneous guidance from clinical best-practice resources^[9].

• Clean the vial stopper and skin with alcohol; allow to dry.
• Pinch a skinfold; insert the needle at 45–90° into subcutaneous tissue^[10][11].
• Do not aspirate for subcutaneous injections; inject slowly and steadily^[10].
• Rotate sites systematically (abdomen, thighs, upper arms) to avoid lipohypertrophy^[12].
• Dispose of used syringes in an approved sharps container; follow local disposal regulations.

Important Note

This content is intended for therapeutic educational purposes only and does not constitute medical advice, diagnosis, or treatment.

References

• 
  Journal of Endocrinology & Metabolism (2014)
  — Safety and metabolism of AOD9604: novel nutraceutical ingredient for improved metabolic health
  View Source
• 
  Journal of Clinical Endocrinology & Metabolism (PubMed)
  — Prolonged stimulation of GH and IGF-I secretion by CJC-1295 in healthy adults
  View Source
• 
  European Journal of Endocrinology (PubMed)
  — Ipamorelin: the first selective growth hormone secretagogue
  View Source
• 
  Translational Andrology and Urology (PMC)
  — Role of growth hormone secretagogues in body composition management
  View Source
• 
  Endocrinology (OUP)
  — hGH and AOD-9604: lipid metabolism and beta-adrenergic pathway insights
  View Source
• 
  CDC
  — Preventing unsafe injection practices: multi-dose vial handling guidelines
  View Source
• 
  Journal of Endocrinology & Metabolism (2013)
  — Safety and tolerability of the hexadecapeptide AOD9604 in humans
  View Source
• 
  Obesity Pharmacotherapy Review (PMC)
  — AOD-9604 clinical trial overview and weight loss outcomes
  View Source
• 
  Subcutaneous Drug Injection Review (PMC)
  — Pharmacologic considerations of the subcutaneous route
  View Source
• 
  CDC
  — Vaccine administration: subcutaneous route (angle/site guidance)
  View Source
• 
  MedlinePlus
  — Subcutaneous injections: patient instructions and technique
  View Source
• 
  NCBI Bookshelf
  — Best practices for injection: asepsis, preparation, and administration
  View Source
• 
  Central & Peripheral Anti-Obesity Targets (PMC)
  — AOD-9604 RCT summary and mechanistic overview
  View Source
• 
  PubMed
  — Metabolic studies of AOD-9604 in obese rodents (oral dosing, fat oxidation)
  View Source